Held by 3 specialist biotech funds
High Convergence# Signal Note: Driehaus Capital Initiates LIVN Position Growth-focused Driehaus's $33.5M entry into LivaNova suggests conviction in the neuromodulation/cardiac device maker's pipeline or operational inflection.
AI analyst context — unlock full analysis
# Signal Note: Deerfield initiates $39.7M stake in LIVN Deerfield's entry into LivaNova suggests confidence in the company's neuromodulation portfolio, particularly its vagus nerve stimulation (VNS) platform for treatment-resistant epilepsy and depression where it holds FDA approvals. The timing may reflect conviction around upcoming clinical catalysts, potential label expansions, or M&A attractiveness given LivaNova's market cap and orphan indication focus. This is a relatively modest position ($39.7M) for a multi-strategy fund, warranting monitoring of Q-level disclosures for additional context on thesis drivers.
+ 1more — see how much conviction went in
See the Full Story